

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”
- NCAB asks for help from administration as NCI deals with deluge of grant applications
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
















